Joaquim Bellmunt
华金·贝尔蒙特
MD, PhD
Professor of Medicine; Director, Bladder Cancer Center医学教授；膀胱癌中心主任
👥Biography 个人简介
Joaquim Bellmunt is an internationally celebrated bladder cancer expert whose KEYNOTE-045 trial established pembrolizumab as second-line standard of care. A founder of major European oncology groups, he has advanced FGFR3-targeted therapy and prognostic models for urothelial carcinoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Pembrolizumab in Second-Line Urothelial Carcinoma
Led KEYNOTE-045 trial demonstrating pembrolizumab improved overall survival versus investigator-choice chemotherapy, securing FDA approval as second-line urothelial carcinoma therapy.
FGFR3 Targeted Therapy and Prognostic Modeling
Advanced erdafitinib trials and developed the Bellmunt prognostic model for platinum-refractory urothelial carcinoma, widely used in clinical trial stratification.
Representative Works 代表性著作
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine (2017)
KEYNOTE-045 establishing pembrolizumab superiority over chemotherapy in second-line advanced urothelial carcinoma, transforming standard of care.
Prognostic Factors in Patients with Advanced Transitional Cell Carcinoma of the Urothelial Tract
Journal of Clinical Oncology (2010)
Defined the Bellmunt prognostic model for platinum-refractory metastatic urothelial carcinoma, providing a validated framework used in global clinical trials.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 华金·贝尔蒙特 的研究动态
Follow Joaquim Bellmunt's research updates
留下邮箱，当我们发布与 Joaquim Bellmunt（Beth Israel Deaconess Medical Center, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment